What is the main business of Aristo Pharma?

The main business activity of Aristo Pharma focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on November 16, 2005.

Where is the headquarters located?

The headquarters is located at: ul. Baletowa 30, 02-867 Warszawa.

What is the share capital?

The share capital of the company is PLN 1,000,000 (approx. $270,124).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

The company reported a revenue of $20,746,556 in 2024, which is an increase of 22.1% compared to 2023.

Yes, in 2024 the company was profitable, achieving a net profit of $1,543,131, meaning the company increased its profit by 19.2%.

What is the main operating cost?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $7,438,125 in 2024, representing 40% of all operating expenses.

Aristo Pharmasp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2005-11-16

Share capital

1 000 000,00 PLN

Activity description

Aristo Pharma has operated since 2005 and offers prescription and over-the-counter medicines, dietary supplements, foods for special medical purposes, medical devices and cosmetics. It develops products in dermatology, gynecology, urology, psychiatry, neurology and family medicine, and has been part of the international Aristo Pharma group since 2019.

Registered address

ul. Baletowa 30, 02-867 Warszawa, Poland

Website

aristo-pharma.pl

Phone

Electronic delivery address

AE:PL-54964-68463-IUGEJ-16

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 16 days early. All were audited by a statutory auditor.

202507/07/2026
202407/07/2025
202309/07/2024
202215/07/2023
202113/06/2022
202006/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 22.78mMedianUSD 1.06mAverageUSD 22.41m

Net profit

This companyUSD 898.48kMedianUSD 37.20kAverageUSD 879.46k

Operating costs

This companyUSD 21.12mMedianUSD 921.66kAverageUSD 21.08m

Assets

This companyUSD 12.11mMedianUSD 609.79kAverageUSD 11.85m

Industry

Trademarks

Aristo Pharma holds 135 active trademarks registered with the Polish Patent Office. 6 applications are pending. 34 marks have expired or were not registered. The first mark was filed in 2002.

Mark	Number	Classes	Status	Protected until
ZYNTAX(word)	Z.586278	5	Protected	Jun 17, 2035
AZETIC(word)	Z.557750	3	Protected	Jul 4, 2033
ONYNAIL(word)	Z.548067	3	Protected	Oct 12, 2032
PAINALGIN(word)	Z.542745	5	Protected	May 5, 2032
LIDEXAN(word)	Z.541960	5	Protected	Apr 12, 2032

Mark	Protected until
ZYNTAX(word)	Jun 17, 2035
AZETIC(word)	Jul 4, 2033
ONYNAIL(word)	Oct 12, 2032
PAINALGIN(word)	May 5, 2032
LIDEXAN(word)	Apr 12, 2032

Authorized Representatives

Robert Andrzej Czernik – President of the Management Board

Barbara Kryza Niemiec – Attorney-in-fact (joint)

Urszula Deszczyńska – Attorney-in-fact (joint)

Joanna Kowalska Malczak – Management Board Member

Marian Komar – Management Board Member

Manner of representation

The President of the Management Board acting independently is authorized to make declarations, sign documents and incur liabilities on behalf of the company; in the case of a multi-member management board, two members of the management board acting jointly are authorized to incur liabilities and sign documents on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Aristo Pharma Gmbh	2,000	$270,124.26	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2006-02-08.

ING Bank Śląski
91 1050 1012 1000 0023 2387 2586
Bank Millennium
42 1160 2202 0000 0002 7855 5530
ING Bank Śląski
65 1050 1012 1000 0023 2793 9100

Debt

No entries in the National Debtors Register (KRZ).

Real estate

Type	Amount
Land (incl. perpetual usufruct)	$413.4K$413,359
Buildings and premises	$669.4K$669,402

MSiG notices

Publication date	Event
Mar 19, 2018	Merger registered

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 1, 2022	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$7,690$7,690	Starosta Piaseczyński

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Optifarmasp. z o.o. + limited partnership	$29,560,928.95	optifarma.com
Antar Medicalsp. z o.o.	$21,453,293.22	antar.net
Bionorica Polskasp. z o.o.	$19,802,926.77	bionorica.pl
Woerwag Pharma Polskasp. z o.o.	$16,858,061.27	woerwagpharma.pl
Ursapharm Polandsp. z o.o.	$16,296,973.60	ursapharm.pl
Qpharmasp. z o.o.	$16,010,159.04	qpharma.pl
Vitamed Pharmaceuticalssp. z o.o.	$14,515,124.01	vitamed.pl
Pharmabestsp. z o.o.	$13,942,252.57	pharmabest.pl
PolypharmS.A.	$13,660,727.48	polypharm.pl
Vipadosp. z o.o.	$11,385,128.54	vipado.pl

Change history

Date	Event
2020-01-10	Name change (Axxon → Aristo Pharma)
2016-12-13	Address change (Puławska 314, 02-819, Warszawa → Ul. Baletowa 30, 02-867, Warszawa)
2015-02-09	PKD change (Removed: 10.89.Z, 20.51.Z, 20.53.Z, 20.59.Z, 26.80.Z, 38.32.Z, 46.11.Z, 46.12.Z, 46.13.Z, 46.14.Z, 46.15.Z, 46.16.Z, 46.17.Z, 46.18.Z, 46.19.Z, 46.38.Z, 46.45.Z, 47.11.Z, 47.75.Z, 68.20.Z, 70.22.Z, 72.11.Z, 72.19.Z, 73.1, 74.20.Z, 74.30.Z, 82.11.Z, 82.30.Z, 82.92.Z, 82.99.Z, 86.10.Z, 86.2, 86.90.B, 86.90.D, 86.90.E)
2014-03-10	PKD change (Added: 10.89.Z, 20.42.Z, 32.50.Z, 46.38.Z, 46.45.Z, 72.11.Z, 72.19.Z)
2011-06-20	Share capital change (50,000.00 PLN → 1,000,000.00 PLN)

FAQ

Last updated: 2026-10-07